JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
about
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studyCurrent concepts in the management of rheumatoid arthritisThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesMatrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysisEffects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes.Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: A case report and review of the literature.Inhibition of IL-17 as a pharmacological approach for IBD.Emerging immunotherapies for rheumatoid arthritis.Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Filgotinib for the treatment of rheumatoid arthritis.Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.IL-17 in the rheumatologist's line of sight.Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model
P2860
Q24658506-DC1CEB28-6DD6-4C30-8AF6-A21690D34320Q26765124-8FF9056E-6D76-4C03-BC2E-D8E951694FBEQ27022645-7DA17E62-3AB7-47F5-BB6C-5796B84BBC97Q33754764-37D864FB-A4A1-4362-A438-C60D0FAB10DEQ34858352-9B2BAB3C-F78F-4501-B8BE-24129EBA1B42Q35064975-0CFD5F5E-3F89-484E-A02C-D725248F95BCQ36761766-61DD2868-D1E0-4181-B9A5-37B5B53B8189Q37388213-E4A481CD-C1AC-4BCC-B9D6-6BA8EC870799Q37552226-097611E8-94AE-41ED-BC37-36F860A32C8AQ38124101-1DBA482A-23D2-4105-A7AC-790D7E113CF4Q38188862-5F2F9C0A-8B72-4771-B177-186C744FCD1CQ38306720-1368EF4D-4D46-4810-A44D-D48A8184A0C9Q38543700-FD192477-D900-4A39-A7F8-CF71F2A90033Q38609755-569048AF-7695-4B35-BFB4-43733A53477BQ38929939-825C7910-3E2D-4E91-A7F3-A4C622653AE1Q38932097-F6992427-C74D-4BC5-9854-6DA1B1F6276EQ41890076-CC006A20-E2F1-4190-8458-1CBD51C6D09BQ56966140-F9014FBD-D318-4F7C-A2B7-C3B77B2C8CED
P2860
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
@en
type
label
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
@en
prefLabel
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
@en
P2860
P1433
P1476
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
@en
P2093
Kunihiro Yamaoka
Yoshiya Tanaka
P2860
P304
P356
10.3109/S10165-012-0799-2
P577
2012-12-05T00:00:00Z